Mitochondria, the mighty energy factories of the cell, often malfunction in cancer, as well as in other conditions such as aging, neurodegenerative disease and heart disease. Whether these changes in mitochondria actually ...
Dec 21, 2016
0
109
A potent cancer-fighting molecule in our cells can be reawakened by reducing levels of a protein – called SET – that's often found in excess in cancer cells, a new study from Columbia University's Herbert Irving Comprehensive ...
Sep 14, 2016
0
92
In the presence of pancreatic tumors, certain immune cells break down structural proteins into molecules that trigger the building of dense tissue, a known barrier to therapy, a new study finds.
Apr 4, 2022
0
27
During brain development, neurons have to migrate long distances through complex environments until they reach their final destination. In order to find guidance, they must establish several interactions—which are still ...
Oct 18, 2022
0
48
Tumor recurrence following a period of remission is the main cause of death in cancer. The ability of cancer cells to remain dormant during and following therapy, only to be reactivated at a later time, frequently with greater ...
Mar 3, 2015
1
128
BOSTON--Researchers at Dana-Farber Cancer Institute have demonstrated a molecular strategy they say could make a much larger variety of tumors treatable with PARP inhibitors, a promising new class of cancer drugs.
Jun 29, 2011
0
0
Despite the great promise that injecting a new type of anti-inflammatory pain medicine into the spine could relieve the severe leg and lower back pain of sciatica, a Johns Hopkins-led study has found that the current standard ...
Apr 16, 2012
0
0
Precision medicine in cancer treatment uses genetic changes in the cancer cells to select the best therapies for individual patients.
Jul 28, 2020
0
127
A team of international researchers has identified a process that functions like a rheostat to dial up cell division by dislodging a tumor suppressor protein that serves as an off switch. The mechanism offers insight into ...
May 1, 2019
0
36
In recent years, much scientific effort and funding has focused on developing drugs that target an enzyme with the unwieldy name of Src homology 2-containing protein tyrosine phosphatase 2 or more briefly, Shp2.
Nov 9, 2021
0
53
